Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis.

被引：0
|
作者：
Jani, Meghna [1 ]
Chinoy, Hector [1 ]
Warren, Richard B. [2 ]
Griffiths, Christopher E. M. [2 ]
Morgan, Ann W. [3 ]
Wilson, Anthony G. [4 ]
Hyrich, Kimme L. [1 ]
Isaacs, John [5 ]
Plant, Darren [1 ]
Barton, Anne [6 ]
机构：
[1] Univ Manchester, Ctr Musculoskeletal Res, Manchester 2, Lancs, England
[2] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Coll Dublin, Dublin, Ireland
[5] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England
[6] Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2924
引用
收藏
页码：S1278 / S1278
页数：1
相关论文
共 50 条
  • [41] PRIOR IMMUNOGENICITY TO ANTI-TNF BIOLOGICS IS NOT ASSOCIATED WITH INCREASED ANTI-DRUG ANTIBODIES TO VEDOLIZUMAB OR USTEKINUMAB
    Costable, Nicholas J.
    Borman, Zachary A.
    Phan, Becky L.
    Ji, Jiayi
    Dubinsky, Marla
    Ungaro, Ryan C.
    GASTROENTEROLOGY, 2020, 158 (06) : S468 - S469
  • [42] Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
    Costable, Nicholas J.
    Borman, Zachary A.
    Ji, Jiayi
    Dubinsky, Marla C.
    Ungaro, Ryan C.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 2480 - 2484
  • [43] Long-term effect of anti-TNF treatment on atherosclerosis risk factors in rheumatoid arthritis patients
    Sayo, Y.
    Dobashi, H.
    Matsubara, S.
    Ishida, I.
    DIABETOLOGIA, 2008, 51 : S538 - S538
  • [44] ANTINUCLEAR ANTIBODIES INDUCED BY ANTI-TNF ALPHA AND ITS IMPACT IN CLINICAL RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS
    Fonseca, R.
    Vieira, R.
    Madureira, P.
    Rosa-Goncalves, D.
    Aguiar, F.
    Rocha, T.
    Bernardo, A.
    Mariz, E.
    Bernardes, M.
    Costa, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 558 - 558
  • [45] DRUG RETENTION AND REASONS FOR DRUG DISCONTINUATION OF ANTI-TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A NETWORK META-ANALYSIS
    Ching, C. P. Lee
    Donath, E.
    Sergeyenko, Y.
    Mai, D.
    Desai, T.
    Shah, A.
    Patel, C.
    Kothadia, S. M.
    Morrison, R. L.
    Lee, C. -C. J.
    Tappy, E.
    Kumar, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 225 - 225
  • [46] Delay in imaging versus clinical response provides rationale for prolonged treatment with anti-TNF in early rheumatoid arthritis.
    Wakefield, Richard J.
    Freeston, Jane E.
    Hensor, Elizabeth M. A.
    Bryer, Domini
    Quinn, Mark A.
    Emery, Paul
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S544 - S544
  • [47] A COST UTILITY ANALYSIS OF ANTI-TNF AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Adams, R. C.
    Walsh, C.
    Schmitz, S.
    Barton, P.
    Barry, M.
    VALUE IN HEALTH, 2011, 14 (07) : A311 - A312
  • [48] ANTI-DRUG-ANTIBODIES BUT NOT IGG-4 ANTIBODIES AGAINST TNF BLOCKERS INFLUENCE THE ACTIVITY OF ANTI-TNF DRUGS IN RHEUMATOID ARTHRITIS
    Benucci, M.
    Infantino, M.
    Manfredi, M.
    Olivito, B.
    Sarzi-Puttini, P.
    Atzeni, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 431 - 431
  • [49] Predicting response to anti-TNF treatment in rheumatoid arthritis patients
    Atzeni, Fabiola
    Antivalle, Marco
    Pallavicini, Francesca Bobbio
    Caporali, Roberto
    Bazzani, Chiara
    Gorla, Roberto
    Favalli, Ennio Giulio
    Marchesoni, Antonio
    Sarzi-Puttini, Piercarlo
    AUTOIMMUNITY REVIEWS, 2009, 8 (05) : 431 - 437
  • [50] Long-term safety of fully human anti-TNF adalimumab in worldwide rheumatoid arthritis clinical trials
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, G
    Kent, JD
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S297 - S297
12345